Anti-MAG antibody-associated polyneuropathies
- 1 August 1995
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 45 (8) , 1577-1580
- https://doi.org/10.1212/wnl.45.8.1577
Abstract
Treatment outcomes of sensory-motor polyneuropathies associated with anti--myelin-associated glycoprotein (MAG) antibodies have varied even with relatively intensive immunosuppression. We used plasma exchange and cyclophosphamide to treat four patients with anti-MAG antibody-associated polyneuropathies whose symptoms had progressed in the preceding year. Treatment courses consisted of five to seven monthly regimens of plasma exchange on 2 consecutive days followed by intravenous cyclophosphamide (1 g/m2). Effects of treatment were quantitatively measured with hand-held dynamometry. All four patients showed improvement in both strength and sensation in the 5 to 24 months after treatment. We conclude that selected patients with sensory-motor polyneuropathies associated with high-titer serum IgM autoantibodies against MAG may have quantitative and useful functional improvement after immunotherapy. The improvement continues after completion of treatment and may persist for 1 to 2 years or longer. NEUROLOGY 1995;45: 1577-1580Keywords
This publication has 7 references indexed in Scilit:
- Levodopa: Rational and irrational pharmacologyAnnals of Neurology, 1994
- Megadose corticosteroids in multiple sclerosisNeurology, 1994
- Message from the editorAnnals of Neurology, 1994
- Axonal transport in neurological diseaseAnnals of Neurology, 1988
- Amyotrophic lateral sclerosis and parkinsonism‐dementia on GuamNeurology, 1986
- An evaluation of ambulatory, cassette EEG monitoringNeurology, 1983
- Cell Type‐Specific Surface Antigens in the Mammalian Nervous SystemJournal of Neurochemistry, 1982